Advertisement Gilead Viread drug proven effective against HBV infection - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Gilead Viread drug proven effective against HBV infection

Gilead Sciences's Viread (tenofovir disoproxil fumarate) has been found effective in treating chronic hepatitis B virus (HBV) infection among primarily treatment-naïve patients.

The new five-year data from the open-label phase of two pivotal Phase 3 clinical trials indicated that Viread maintains long-term viral suppression of HBV and reduces liver fibrosis and cirrhosis.

During the studies 102 and 103, 88% of the subjects have shown improvement in overall liver histology.

The principal investigator of Study 102, Patrick Marcellin, said the long-term antiviral therapy can not only help chronic hepatitis B patients achieve and maintain virologic suppression, but also help to improve clinical outcomes.

"These results represent an important advance in HBV therapy because they elucidate Viread’s potential to reduce or reverse signs of liver damage in patients with chronic hepatitis B," Patrick Marcellin added.

The multi-center, randomized, double-blind studies 102 and 103 were designed to compare Viread to Hepsera (adefovir dipivoxil) among both HBeAg-negative (Study 102) and HBeAg-positive (Study 103) patients with compensated liver disease.